GleamWall
中文EN

EMMA Emmaus Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.0%
TTM net income YoY-77.9%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR-18.2%
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin29.3%
Net margin-38.8%
FCF margin—
EBITDA margin29.7%

Returns

ROE—
ROA-30.3%
ROIC (approx.)—
Asset turnover0.78x

Leverage & solvency

Liabilities / assets504.3%
Debt / equity—
Current ratio0.09x
Interest coverage0.57x

Cash quality & payout

Operating cash flow / net income-0.66x
Accruals ratio-50.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$6.32M$1.98M$3.85M$3.38M$2.82M$2.41M$3.29M$5.48M
Cost of revenue$344,000$168,000$235,000$247,000$150,000$225,000$309,000$394,000
Gross profit$5.97M$1.81M$3.62M$3.13M$2.67M$2.18M$2.98M$5.08M
R&D expense$116,000$40,000$31,000$50,000$56,000$176,000$137,000$146,000
SG&A expense$1.57M$1.85M$1.80M$1.73M$2.31M$2.34M$2.29M$2.80M
Operating income$3.79M-$823,000$886,000$695,000-$370,000-$980,000-$557,000$821,000
Interest expense$1.60M$2.13M$2.27M$1.93M$1.68M$1.26M$1.28M$1.34M
Pretax income$1.34M-$3.33M-$1.94M-$1.50M-$1.73M-$2.33M-$1.74M$1.83M
Income tax-$1,000$4,000$16,000$579,000-$590,000$4,000$6,000-$1,000
Net income$1.34M-$3.33M-$1.95M-$2.08M-$1.14M-$2.33M-$1.75M$1.83M
EBITDA$3.81M-$808,000$901,000$710,000-$366,000-$975,000-$552,000$826,000
EPS (basic)0.02-0.05—-0.03-0.02-0.04—0.03
EPS (diluted)0.02-0.05—-0.03-0.02-0.04—0.03
Weighted avg. shares (diluted)120.54M70.19M—63.87M63.87M63.87M—63.87M
Balance sheet
Cash & equivalents$2.81M$1.07M$2.13M$293,000$886,000$1.33M$1.39M$1.25M
Receivables$709,000$2.05M$2.80M$2.62M$2.07M$2.06M$2.62M$4.94M
Inventory$1.59M$1.91M$1.55M$1.21M$1.31M$1.44M$1.64M$1.61M
Current assets$6.00M$6.00M$7.75M$4.79M$5.01M$5.65M$6.77M$9.20M
PP&E, net$86,000$98,000$113,000$128,000$143,000$41,000$46,000$49,000
Total assets$16.37M$18.70M$21.44M$20.76M$23.34M$22.48M$23.60M$27.34M
Current liabilities$66.12M$70.54M$69.07M$64.17M$62.08M$64.92M$63.55M$64.13M
Long-term debt$24.99M$26.56M$27.13M$29.07M$29.73M$29.01M$28.96M$29.30M
Total debt$24.99M$26.56M$27.13M$29.07M$29.73M$29.01M$28.96M$29.30M
Total liabilities$82.55M$86.56M$85.04M$80.24M$79.05M$81.08M$80.08M$81.12M
Shareholders' equity-$66.18M-$67.86M-$63.61M-$59.49M-$55.70M-$58.60M-$56.48M-$53.78M
Net debt$22.18M$25.49M$25.00M$28.78M$28.85M$27.67M$27.58M$28.04M
Shares outstanding70.19M70.19M70.19M63.87M63.87M63.87M63.87M63.87M
Cash flow statement
Operating cash flow$1.69M-$344,000$2.21M$409,000-$2.91M$279,000$343,000$148,000
Capital expenditure——$0$0——$6,000-$1,000
Free cash flow——$2.21M$409,000——$337,000$149,000
Investing cash flow$1.58M$0$0$0$2.17M$0-$2,000$1,000
Financing cash flow-$1.53M-$702,000-$362,000-$1.00M$284,000-$345,000-$195,000-$438,000
Depreciation & amortization$14,000$15,000$15,000$15,000$4,000$5,000$5,000$5,000
Stock-based compensation$0$1,000$7,000$9,000-$1,000$10,000$29,000$28,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.